Abstract
Angiotensin receptor blockers (ARBs) are a new class of drug that has entered the hypertension market within the last five years. This class, although similar to angiotensin converting enzyme (ACE) inhibitors in their renal cardiovascular effects, has a different mechanism of action. By directly blocking the receptor, ARBs can have specific effects on systems that are affected by angiotensin II. Because of this differential effect, this class of drugs is better tolerated by patients, as is evident in lower side-effect profiles with ARB use when compared with ACE inhibitors. This article reviews the data from all available, well-designed studies in the elderly with regard to ARB use related to hypertension and renal disease.